HEMISPHERIAN AS
Developing novel small molecule drugs targeting TET2 for aggressive cancers.
Yleiskatsaus
- 5
- Työntekijät
- 269t NOK
- Liikevaihto
- 2020
- Perustettu
Avainpäättäjät
Zeno Albisser
Chief Executive Officer
Wolfram Eichner
Director
Adam Robertson
Chief Scientific Officer
Terezia Prikrylova
Chief Operating Officer
+15 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...